ARTV
Artiva Biotherapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
10.93
▼ 0.21 (1.89%)
MARKET · —
Price
Open
11.14
Prev close
11.14
Day high
11.60
Day low
10.76
Volume
198.31K
Market cap
$534.37M
P/E (TTM)
—
52W range
2.22 – 14.53
Trailing performance
Returnvs SPY
1W
-4.54%
-3.2%
1M
+7.90%
+4.2%
3M
+36.80%
+33.7%
6M
+133.55%
+122.5%
YTD
+154.78%
+142.5%
1Y
+303.32%
+283.3%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$534.37M
Enterprise value$194.82M
Revenue (TTM)—
Gross profit—
EBITDA$-93.46M
Net income$-90.82M
EPS (TTM)$-3.23
Free cash flow$-44.43M
Total cash$349.39M
Total debt$9.85M
Book value / share$7.12
Shares outstanding48.89M
Float21.35M
Short % of float5.60%
Dividend yield—
Beta (5Y)2.18
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.19
PEG ratio—
Price / sales—
Price / book1.53
EV / revenue—
EV / EBITDA-2.09
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-36.58%
Return on assets-22.34%
Debt / equity2.83
Current ratio24.16
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total revenue | $0 | $251.00K | $0 |
| Cost of revenue | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 |
| R&D | — | — | — |
| SG&A | — | — | — |
| Operating income | — | — | — |
| Pre-tax income | — | — | — |
| Tax provision | $0 | $0 | $0 |
| Net income | -$83.86M | -$65.37M | -$28.72M |
| EBIT | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash & equivalents | — | — | — |
| Short-term investments | — | — | — |
| Net receivables | — | — | — |
| Inventory | — | — | — |
| Total current assets | — | — | — |
| Total assets | — | — | — |
| Total current liabilities | — | — | — |
| Long-term debt | — | — | — |
| Total liabilities | — | — | — |
| Retained earnings | — | — | — |
| Shareholder equity | — | — | — |
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net income | -$83.86M | -$65.37M | -$28.72M |
| Depreciation | — | — | — |
| Change in working capital | — | — | — |
| Operating cash flow | — | — | — |
| Capital expenditure | — | — | — |
| Investing cash flow | — | — | — |
| Dividends paid | — | — | — |
| Buybacks | — | — | — |
| Financing cash flow | — | — | — |
| Net change in cash | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.64 | -0.63 | +2.0% |
| Mar 2026 | -0.84 | -0.95 | -12.7% |
| Dec 2025 | -0.80 | -0.84 | -5.0% |
| Sep 2025 | -0.80 | -0.88 | -10.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.53 | 5 | $0 | 0.0% |
| Next quarter | -0.58 | 5 | $0 | 0.0% |
| Current year | -2.51 | 5 | $0 | 0.0% |
| Next year | -2.61 | 5 | $0 | 0.0% |
Analyst targets & ownership
Mean target$35.80
High target$41.00
Low target$23.00
Implied upside227.54%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders14.89%
Held by institutions84.05%
Institutions holding92
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+10.33M
Net buying
Buy transactions
14
10.39M shares
Sell transactions
6
53.47K shares
Net transactions
+20
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
7.28M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | BANERJEE SUBHASHIS M.D. Officer |
CONVERSION | 429 | $824 | Direct |
| Aug 18, 26 | BANERJEE SUBHASHIS M.D. Officer |
SELL | 429 | $5.15K | Direct |
| Jul 31, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 45.77K | $455.73K | Indirect |
| Jul 24, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 41.32K | $412.78K | Indirect |
| Jul 23, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 264.59K | $2.58M | Indirect |
| Jul 17, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 160.35K | $1.43M | Indirect |
| Jul 13, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.65K | $194.04K | Indirect |
| Jul 13, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.62K | $193.77K | Indirect |
| Jun 26, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 32.88K | $292.13K | Indirect |
| Jun 16, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 531.33K | $4.60M | Indirect |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.03M | $7.65M | Indirect |
| May 19, 26 | BUSH JENNIFER KINSBRUNER Chief Operating Officer |
SELL | 8.79K | $79.18K | Direct |
| May 19, 26 | HORAN CHRISTOPHER Chief Operating Officer |
SELL | 7.00K | $63.07K | Direct |
| May 19, 26 | ASLAN FRED M.D. Chief Executive Officer |
SELL | 27.12K | $244.25K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ASLAN FRED M.D. |
Chief Executive Officer | 1.54M | Sale |
BANERJEE SUBHASHIS M.D. |
Officer | 144.96K | Conversion of Exercise of derivative security |
BUSH JENNIFER KINSBRUNER |
Chief Operating Officer | 337.92K | Sale |
GC CORP |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
GRAEF THORSTEN |
Officer | 80.00K | Stock Award(Grant) |
HORAN CHRISTOPHER |
Chief Operating Officer | 293.45K | Sale |
HUSTON THAD ALLEN |
Chief Financial Officer | 220.00K | Stock Award(Grant) |
KRISHNAMOHAN NEHA |
Chief Financial Officer | 110.00K | Stock Award(Grant) |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RAYMON HEATHER |
Officer | 148.23K | Sale |
Moving averages & technicals
SMA 10
11.45
-4.52% from price
SMA 20
11.11
-1.59% from price
SMA 50
10.12
+8.06% from price
SMA 100
9.56
+14.30% from price
SMA 200
7.01
+55.88% from price
EMA 12
11.27
-3.02% from price
EMA 26
10.86
+0.61% from price
EMA 50
10.26
+6.50% from price
RSI (14)
51.2
Neutral
MACD (12,26,9)
0.41
Hist -0.08
ATR (14)
0.79
7.21% of price
Realised vol 30D
70.1%
Annualised
Bollinger upper
12.21
20, 2σ
Bollinger lower
10.00
20, 2σ
50 / 200 cross
Golden
10.12 vs 7.01
Trend bias
Above 200
+55.88%
Risk profile
Beta vs SPY
2.01
More volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
70.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-49.2%
Peak to trough
Max drawdown 5Y
-90.7%
Peak to trough
ATR 14
0.79
7.21% of price
Beta (reported)
2.18
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
0.00
Positioning, not flow
Max pain
10.00
-8.5% from spot
ATM implied vol
220.3%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
10.00
35 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 16d ago
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 36d ago
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
Zacks · 45d ago
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
GlobeNewswire · 60d ago
Artiva Biotherapeutics Reports Positive AlloNK Data Across Autoimmune Diseases at EULAR 2026
MT Newswires · 75d ago
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
GlobeNewswire · 75d ago
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
GlobeNewswire · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.